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Abstract
Background: Transcatheter aortic valve implantation (TAVI) is presently a recognized treatment mo-
dality for patients with severe aortic stenosis ineligible for surgery. It reduces mortality as compared to 
the conservative treatment. It is further expected from this therapy to improve quality of life by improving 
of the cardiovascular function performance. The aim of this study is to compare patients’ cardiovascular 
system efficiency in the 6-minute walk test (6MWT) made before and after TAVI and at the 6–12-month 
follow-up.
Methods: From January 2009 until February 2012, in the Silesian Center for Heart Diseases in 
Zabrze, TAVI was performed in 104 patients. Eighty-two patients who underwent 6MWT before surgery 
were qualified for the analysis. The average age of the patients was 76.0 ± 9.17 years, women made 
45.1%. The risk of surgical treatment according to the Logistic Euroscore averaged 22.76 ± 12.63%, 
and by the Society of Thoracic Surgeons — 5.55 ± 3.34%. The 6MWT was performed within 1 month 
before the TAVI procedure, up to a month after the procedure and during the 6–12-month follow-up.
Results: The 6-minute walk test after TAVI was performed by 64 patients, and after 6–12 month 
follow-up by 46 patients. The average distance in 6MWT increased from 268.4 ± 89.0 m before treat-
ment to 290.0 ± 98.2 m after the procedure (p = 0.008) and 276.1 ± 93.5 m to 343.1 ± 96.7 m after 
6–12 months (p < 0.0001).
Conclusions: Transcatheter aortic valve implantation procedures significantly improve function of the 
cardiovascular system evaluated by the 6MWT in 1- and 6–12-month observations. (Cardiol J 2017; 
24, 2: 167–175)
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Introduction
Transcatheter aortic valve implantation (TAVI) 
is now a recognized therapy for patients with severe 
aortic stenosis with contraindications to surgery 
or ineligible for surgery because of the high risks 
associated with therapy. TAVI procedure reduces 
mortality in inoperable elderly patients compared 
with conservative treatment [1]. TAVI can achieve 
comparable or better results in terms of survival 
after treatment in elderly patients who require the 
procedure of surgical aortic valve replacement, but 
they are at their high risk related with this therapy 
as compared to surgical treatment [2, 3].
In addition, the therapy is also expected to 
improve the quality of life, i.a. by improving the ef-
ficiency of the cardiovascular system. It may be dif-
ficult to achieve due to the elderly age of the patients 
and the presence of comorbidities. The efficiency of 
the cardiovascular system can be assessed on the 
basis of efficiency tests, such as an exercise test, 
spiroergometric test and simply performable 6-min-
ute walk test (6MWT). This test is optimal to use in 
elderly patients with aortic stenosis, as it allows to 
estimate the capacity of the cardiovascular system 
and to evaluate the symptoms associated with aortic 
stenosis [4–7]. There are few data in the literature 
on the 6MWT in patients undergoing TAVI [4–7]. 
These data are insufficient because they are related 
to the population of patients at a very old age with 
many different comorbidities and they are usually 
short-term observations.
The aim of this study was to evaluate the ef-
ficiency of the cardiovascular system in patients be-
fore and 30 days after TAVI and at the 6–12-month 
follow-up based on the 6MWT.
Methods
From January 2009 to February 2012, in the 
Silesian Center for Heart Diseases in Zabrze, TAVI 
was performed in 104 patients. The patients were 
qualified for the treatment by the multidisciplinary 
team (Heart Team). Patients with severe sympto-
matic aortic stenosis, with a surface area of aortic 
valve in echocardiography (Echo) < 1 cm2, who 
were inoperable or for whom the risk of surgery by 
Logistic EuroScore was > 20% and/or by the Socie-
ty of Thoracic Surgeons (STS) was > 10%, were 
qualified for the procedure. Of the 82 selected pa-
tients, 46 (56.1%) had Logistic EuroScore > 20%, 
and 8 (9.8%) had STS > 10%. Other patients with 
lower risk (Logistic EuroScore was < 20), but with 
comorbidities not covered in the scales of risk, 
however increasing the risk of surgical treatment 
(e.g. liver failure, porcelain aorta, the state after 
radiotherapy) were also qualified for TAVI. The 
lowest Logistic EuroScore was 1.5, the highest 
risk was 61.5%. The lowest risk assessed by the 
STS was 0.45, the highest risk by STS was 14.4%.
Among 36 (43.9%) patients with Logistic Euro - 
Score < 20%: 10 (12.2%) patients had coronary 
artery bypass grafting with the opening of the 
chest. Twelve (14.6%) patients had porcelain aorta. 
Five (6.1%) patients had a surgical valve replace-
ment procedure. Nine (11%) patients had multiple 
diseases not recognized in the scales of risk. The 
Heart Team decided to reject the surgery.
Out of 104 patients treated with TAVI, 
82 patients underwent 6MWT before TAVI. The re-
maining 22 patients did not undergo 6MTW before 
TAVI for various reasons (patient’s refusal, logistic 
problems, poor mobility, and other) (Table 1).
Only those patients (n = 82) who underwent 
6MWT before TAVI were enrolled to prospective 
analysis (Fig. 1).
Of the 82 patients who performed 6MWT before 
TAVI, 64 patients underwent 6MWT after TAVI in 
30-day follow-up and 18 patients did not do 6MTW 
after TAVI in 30-day follow-up (Fig. 2, Table 2).
Of the 82 patients who performed 6MWT 
before TAVI and in 30-day follow-up, 46 patients 
Table 1. Six patients who did not undergo 6-minute walk test (6MWT) before transcatheter aortic valve 
implantation for logistic reasons.
Patient number 30-day follow-up 6MWT [m] 6–12-month follow-up 6MWT [m]
1 250 231
2 272 Died
3 No data Died
4 30 s walk — dyspnea 189
5 Valve not implanted — died –
6 Valve not implanted — died –
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Figure 1. Six-minute walk test (6MWT) before transcatheter aortic valve implantation (TAVI); NYHA — New York Heart 
Association.
Figure 2. Six-minute walk test (6MWT) in 30-day follow-up; NYHA — New York Heart Association; TAVI — transcath-
eter aortic valve implantation.
underwent 6MWT after TAVI in 6–12-month 
follow-up and 36 patients did not do 6MTW after 
TAVI in 6–12-month follow-up (Fig. 3).
In 82 patients, 19 (23.2%) Edwards-SAPIEN 
valves (Edwards Lifescience, Irvine, California) 
and 63 (76.8%) CoreValve valves (Medtronic, 
Mineapolis, MN, USA) were implanted.
TAVI procedure was performed via the femo-
ral artery in 50 (61.0%) patients, through the 
subclavian artery — in 17 (20.7%), through the 
ascending aorta — in 2 (2.4%), and through the 
apex of the heart — in 13 (15.9%) patients. The 
procedures were performed after the evaluation 
by the multidisciplinary team (Heart Team). The 
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patients expressed their informed consent to the 
proposed treatment. The procedures were per-
formed in the catheterization laboratory or in the 
hybrid operating theatre. Procedures performed 
transapically, transaortically, through subclavian 
artery and part of the procedures via the femoral 
artery were performed under general anesthesia 
and with the surgical exposing of the access site. 
Other procedures via the femoral artery were 
performed in deep sedation, percutaneously, under 
local anesthesia using vascular closers (Prostar, 
Proglide).
Before implantation, balloon aortic valvu-
loplasty was performed while pacing the right 
ventricle. Edwards-SAPIEN valve sizes of 23, 25 
and 29, and CoreValve valve sizes of 26, 29, 31 
were implanted. The procedures were carried out 
routinely, as described in previous publications 
[8–10]. The 6MWT was performed according to 
the standard procedure in accordance with the 
guidelines of the American Thoracic Society [11], 
within a month before TAVI, up to a month after 
TAVI, and at the 6–12-month follow-up. In patients 
with New York Heart Association (NYHA) class IV, 
6MWT was not performed. The patients had to be-
stride a 30-m hospital corridor. The subjects were 
encouraged to pass the largest distance in 6 min at 
their own pace. Before and after the 6MWT blood 
pressure, heart rate and oxygen saturation were 
recorded. The distance covered by the patient, the 
cause of the end of the test, if it was finished ahead 
of 6 min time, and symptoms occurring during 
Table 2. Seven patients who did not undergo 6-minute walk test (6MWT) in 30-day follow-up for  
logistic reasons.
Patient number 30-day follow-up 6MWT [m] 6–12-month follow-up 6MWT [m]
1 No data No data (patient alive)
2 No data 403
3 No data No data (patient alive)
4 No data No data (patient alive)
5 No data No data (patient alive)
6 No data Died (at 3 month)
7 No data Died (at 2 month)
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Figure 3. Six-minute walk test (6MWT) in 6–12-month follow-up; TAVI — transcatheter aortic valve implantation.
exercise were registered. At the end of the test, 
dyspnea level was determined using a modified 
Borg scale [12–14]. Before TAVI and during the 
follow-up appointments, the degree of efficiency of 
the cardiovascular system according to the NYHA 
scale was determined.
Before, after TAVI, and during the follow-up 
appointments, an experienced cardiologist per-
formed the echocardiogram with Philips iE 33 
xMATRIX and GE Vivid E9 device.
Statistical analysis
The received figures were expressed as mean 
± standard deviation. In order to examine the 
compatibility of distributions with the normal dis-
tribution Kolmogorov-Smirnov test was used. If 
the distributions of the two variables in a pair were 
consistent with the normal one, T-test was used, 
and if the result was significant, error bars chart 
was made (mean and 95% confidence interval). 
If at least one of the distributions of variables in 
a pair differed significantly from the normal one, 
the Wilcoxon test was used, and if the test showed 
significant differences, a box chart was made (with 
marked quartiles and the typical area). To test 
changes in ordinal variables pairs, Wilcoxon test 
was used, and to test changes in nominal variables 
pairs — a sign test was used and frequency tables 
were made. The level of statistical significance was 
set at p < 0.05. The calculations were performed 
using IBM SPSS 22.0 software.
Results
Patient characteristics are shown in Table 3. 
The results of the 6MWT are given in Table 4.
In the 6MWT performed 30 days after TAVI, 
the distance did not increase in 21 (32.8%) patients, 
while in the 6MWT made 6–12 months after the 
TAVI, the distance did not increase in 12 (26.1%) 
patients.
Rating of the capacity of the cardiovascular 
system according to the NYHA scale
Before TAVI, out of 82 patients, 1 (1.2%) was 
in NYHA class I, 34 (41.5%) — in class II, and 47 
(57.3%) — in class III. Thirty days after TAVI, 8 
(11.9%) patients were in NYHA class I, 46 (68.7%) 
— class II, 10 (14.9%) — in class III, and 3 (4.5%) 
— in NYHA class IV. Before TAVI, cardiovascular 
fitness according to NYHA averaged 2.54 ± 0.53, 
and 30 days after TAVI — 2.12 ± 0.66. There was 
a significant decrease in the NYHA class range 
immediately after the procedure (p < 0.0001). In 
the 6–12-month follow-up, 14 (30.4%) patients 
were in NYHA class I, 29 (63.0%) — class II, and 
3 (6.5%) — class III. In the 6–12-month follow-up 
after the TAVI, cardiovascular fitness according to 
NYHA averaged 1.76 ± 0.57. In the medium-term 
follow-up, a significant decrease in the NYHA class 
(p < 0.0001) was noted.
During 30-day follow-up, 43 (67.2%) patients 
had improvement in efficiency of the cardiovascular 
system. Distance amounted to 309.2 ± 84.9 m, 
Table 3. Clinical characteristics of patients.
N 82
Age [years] 76 ± 9.17 [42–90]
Women 37 (45.12%)
Height [m] 1.64 ± 0.09
Body mass [kg] 77 ± 12.95
Body mass index [kg/m2] 28.8 ± 4.61
Cigarette smokers 34 (41.46%)
Diabetes 32 (39.02%)
Hypertension 57 (69.51%)
Creatinine level in blood  
serum [μmol/L]
100.67 ± 45.52
GFR [mL/min/1.73 m2] 70.23 ± 30.22
Patients with renal failure  
(GFR < 60 mL/min/1.73 m2)
34 (43.04)*
COPD 20 (24.39%)
A history of past MI 25 (30.49%)
Condition after CABG 23 (28.05%)
Condition after pacemaker  
implantation
17 (20.73%)
Patients with PH > 60 mm Hg 11 (23.4%)**
SBP in the right ventricle  
[mm Hg]
49.46 ± 16.04
History of the past BAV 12 (14.63%)
Logistic EuroScore [%] 22.76 ± 12.63
EuroScore standard 10.75 ± 3.56
STS [%] 5.55 ± 3.34
LVEF [%] 45 ± 12.21
Sufficiency of the cardiovascular 
in NYHA:
Class I 1 (1.2%)
Class II 34 (41.5%)
Class III 47 (57.32)
*n = 79; **n = 47; CABG — coronary artery bypass graft; COPD — 
chronic obstructive pulmonary disease; BAV — balloon aortic valvu- 
loplasty; GFR — glomerular filtration rate; Logistic EuroScore — 
Logistic European System for Cardiac Operative Risk Evaluation; 
LVEF — left ventricular ejection fraction; MI — myocardial infarction; 
NYHA — New York Heart Association; PH — pulmonary hypertension; 
SBP — systolic blood pressure; STS — Society of Thoracic  
Surgeons score
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prior to TAVI was 247 ± 82.1 m (p = 0.001). 
Twenty-one (32.8%) patients did not achieve better 
results during the 6MWT. Distance among them 
was 250.7 ± 113.3 m, prior to TAVI it was 312.3 ± 
± 88.4 m (p = NS).
During the 6–12-month follow-up, 34 (73.9%) 
patients had improvement in efficiency of the 
cardiovascular system. Distance among them was 
360 ± 102.8 m, before TAVI it was 254.1 ± 88.7 m 
(p < 0.0001). Twelve (26.1%) patients did not 
achieve better results during the 6MWT. Distance 
among them was 295.4 ± 56.7 m, prior to TAVI it 
was 338.2 ± 80.5 m (p = NS).
Of the patients in NYHA class IV before TAVI, 
5 (55.6%) patients finished 6MWT during the 
30-day follow-up, and 5 (55.6%) patients finished 
6MWT during the 6–12-month follow-up (Fig. 1, 
Table 5).
Cardiovascular performance and physical fit-
ness after TAVI are displayed in Table 6.
Table 4. Six-minute walk test (6MWT) results.
6MWT 6MWT  
before TAVI  
(n = 64)
6MWT 30-day  
follow-up  
(n = 64)
P 6MWT  
before TAVI  
(n = 46)
6MWT 
6–12-month  
follow-up  
(n = 46)
P
Distance [m] 268.4 ± 89.0 290.0 ± 98.2 0.008 276.1 ± 93.5 343.1 ± 96.7 < 0.0001
Systolic pressure before  
the 6MWT [mm Hg]
119 ± 18 123 ± 17 0.094 119 ± 20 131 ± 16 0.002
Diastolic blood pressure  
before the 6MWT [mm Hg]
71 ± 10 71 ± 9 1.0 70 ± 10 75 ± 9 0.009
Heart rate before 6MWT [/min] 73 ± 13 76 ± 14 0.044 73 ± 14 74 ± 12 0.416
Arterial blood oxygen  
saturation before 6MWT [%]
96.1 ± 1.7 96.4 ± 1.6 0.353 96.0 ± 1.8 96.3 ± 1.4 0.168
Systolic blood pressure after 
6MWT [mm Hg]
135 ± 22 143 ± 21 0.006 134 ± 23 147 ± 18 0.002
Diastolic blood pressure after 
6MWT [mm Hg]
72 ± 9 73 ± 8 0.608 71 ± 9 76 ± 8 0.016
Heart rate after 6MWT [/min] 84 ± 13 91 ± 14 0.001 84 ± 14 91±15 0.007
Arterial blood saturation after 
6MWT [%]
96.0 ± 2.7 95.7 ± 2.5 0.550 95.7 ± 3.0 95.4 ± 2.2 0.359
Modified Borg scale after 
6MWT
3.22 ± 1.4 2.64 ± 1.0 0.011 3.0 ± 1.5 2.6 ± 1.5 0.123
Pain in the chest after 6MWT 13 (20.3%) 3 (4.7%) 0.006 8 (17.4%) 1 (2.2%) 0.016
Dyspnea/fatigue after 6MWT 50 (78.1%) 39 (60.9%) 0.035 34 (73.9%) 33 (71.7%) 1.000
Pain in the lower limbs after 
6MWT
44 (68.8%) 40 (62.5%) 0.424 33 (71.7%) 27 (58.7%) 0.070
Significant increase or  
decrease in blood pressure 
after 6MWT
0 (%) 0 (0%) 1.000 0 (0%) 0 (0%) 1.000
Arrhythmias after 6MWT 0 (0%) 0 (0%) 1.000 0 (0%) 0 (0%) 1.000
TAVI — transcatheter aortic valve implantation
Rating of the capacity of the cardiovascular 
system according to the echocardiographic 
parameters
During 30-day follow-up, in 64 (78%) patients, 
echocardiographic parameters of the aortic valve 
improved. Left ventricular ejection fraction [%] did 
not change (48.2 ± 10.0 before TAVI to 47.8 ± 10.9 
in 30-day follow-up, p = NS). Aortic valve surface 
area [cm2] increased (0.7 ± 0.3 before TAVI to 
1.7 ± 0.6 in 30-day follow-up, p < 0.0001). Index of the 
aortic valve surface area [cm2/m2] increased (0.3 ± 
± 0.1 before TAVI to 0.9 ± 0.3 in 30-day follow-
-up, p < 0.0001). The average gradient through the 
aortic valve [mm Hg] decreased (53.3 ± 17.8 before 
TAVI to 9.2 ± 6.1 in 30-day follow-up, p < 0.0001).
During the 6–12-month follow-up, in 46 
(56.1%) patients, echocardiographic parameters of 
the aortic valve improved. Left ventricular ejection 
fraction [%] did not change (48.3 ± 9.8 before TAVI 
to 49.5 ± 11.0 in 6–12-month follow-up, p = NS). 
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Table 5. Patients in NYHA class IV before trans-
catheter aortic valve implantation.
Patient  
number
30-day  
follow-up  
6MWT [m]
6–12-month  
follow-up  
6MWT [m]
1 Still NYHA class IV Died
2 460 461 
3 340 410 
4 63 90 
5 Died Died
6 Still NYHA class IV 189 
7 Died Died
8 330 Died
9 195 265
6MWT — six-minute walk test; NYHA — New York Heart Association
Aortic valve surface area [cm2] increased (0.7 ± 
± 0.3 before TAVI to 1.7 ± 0.5 in 6–12-month fol-
low-up, p < 0.0001). Index of the aortic valve sur-
face area [cm2/m2] increased (0.4 ± 0.2 before TAVI 
to 0.9 ± 0.3 in 6–12-month follow-up, p < 0.0001). 
The average gradient through the aortic valve 
[mm Hg] decreased (51.6 ± 16.6 before TAVI to 
9.0 ± 4.0 in 6–12 month follow-up, p < 0.0001).
Discussion
As a result of TAVI, hemodynamic parameters 
of aortic failure, such as a reduction in average 
gradient and an increase in aortic valve surface 
area, were improved. The hemodynamic failure pa-
rameters improvement reached immediately after 
the surgery remained on the same level creating 
conditions to improve exercise tolerance evaluated 
in the 6MWT, and to improve the efficiency of the 
cardiovascular system, evaluated according to the 
NYHA classification. Many studies evaluating the 
results of TAVI showed remarkable improvement 
in the echocardiography parameters of aortic failure 
and in the capacity of the cardiovascular system, 
evaluated according to NYHA classification [1, 2, 4].
The 6MWT is easy to perform, does not re-
quire any professional equipment, and can deter-
mine the overall exercise capacity of patients [11]. 
Exercise tolerance depends on the function of many 
systems, including the cardiovascular system. The 
6MWT is used to assess exercise tolerance in 
patients with various diseases of the respiratory 
and cardiovascular system. It is also carried out 
before and after an appropriate method of treat-
ment to evaluate its efficacy in various diseases of 
respiratory and cardiovascular systems [11]. It can 
be safely performed in older patients with heart 
failure and cardiomyopathies [11, 12, 14].
In their study, Gotzmann et al. [4] evaluated 
44 patients after implantation of aortic CoreValve 
by TAVI method. The patients, 30 days after TAVI, 
covered significantly longer distance when com-
pared to the 6MWT test taken before TAVI (204 ± 
± 103 m vs. 266 ± 123 m, p < 0.001) [4]. Bagur 
et al. [5] evaluated the usefulness of the 6MWT 
in 64 patients who underwent TAVI. Six months af-
ter TAVI they achieved a significant increase in the 
distance covered during the test (165.3 ± 79.7 m 
before TAVI to 231.7 ± 88.9 m 6 months after 
TAVI, p < 0.0001).
The authors of this study noted that there are 
about 25% patients out of the study group, in whom 
there was no growth or even a decline in the dis-
Table 6. Cardiovascular performance and  
physical fitness after transcatheter aortic valve 
implantation (TAVI).
30-day follow-up
Longer distance in 6MWT 43 (67.2%)
No improvement 21 (32.8%)
Including:
Dyspnea/fatigue (not present before 
TAVI) and leg pain (present before TAVI)
3 (4.7%)
Dyspnea/fatigue (present before TAVI) 
and leg pain (present before TAVI)
4 (6.3%)
Dyspnea/fatigue (present before TAVI) 
and leg pain (not present before TAVI)
2 (3.1%)
Leg pain (present before TAVI) 5 (7.8%)
Dyspnea/fatigue (present before TAVI) 3 (4.7%)
No symptoms 4 (6.3%)
6–12-month follow-up
Longer distance in 6MWT 34 (73.9%)
No improvement 12 (26.1%)
Including:
Dyspnea/fatigue (not present before 
TAVI)
2 (4.3%)
Dyspnea/fatigue (not present before 
TAVI) and leg pain (not present  
before TAVI)
1 (2.2%)
Dyspnea/fatigue (not present before 
TAVI) and leg pain (present before TAVI)
2 (4.3%)
Dyspnea/fatigue (present before TAVI) 
and leg pain (present before TAVI)
5 (10.9%)
Dyspnea/fatigue (present before TAVI) 1 (2.2%)
Dyspnea/fatigue (present before TAVI) 
and leg pain (present before TAVI) and 
pain in the chest (present before TAVI)
1 (2.2%)
6MWT — six-minute walk test
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tance achieved in the 6MWT. Kleczyński et al. [7] 
evaluated 40 patients after the TAVI. After 
12 months, they reported the largest increase in the 
walking distance in the 6MWT. It went up from 
200 m before treatment to 325 m 12 months after 
TAVI. In the present study, 82 patients who under-
went 6MWT prior to surgery and 6–12 months after 
surgery were evaluated. Not only the length of 
distance, but also various parameters of the effort 
test were rated, finding out that most of them 
improved after TAVI procedure. In this study, the 
distance in long-term follow-up increased from 
276.1 ± 93.5 m before the surgery to 343.1 ± 96.7 m 
after the surgery (p < 0.0001).
Initially, it was the longest distance observed 
in patients before TAVI and these patients achieved 
the longest distance after the surgery in the 
6–12-month follow-up. These differences may be 
due to the characteristics of the group of people 
eligible for TAVI, age, comorbidities, as well as the 
fact that the 6MWT was not carried out among the 
most seriously ill (NYHA IV e.g.).
The PARTNER study showed comparable 
survival in patients after TAVI and patients after 
cardiac surgical treatment, and the study of Ad-
ams et al. [3] showed improvement in survival in 
the group treated by TAVI [2]. In addition to the 
observed improved survival, some studies also 
reported the improvement in life quality compared 
with the cardiac surgical therapy [7]. Life qual-
ity improvement can be also assessed indirectly 
through the 6MWT, which is an objective test 
reflecting everyday life activity. In the present 
study, no improvement in the 6MWT was observed 
in 32.8% of patients after 30 days, and after 6–12 
months, still no improvement was noted in 23% 
of patients. Similar observations were made by 
Bagur et al. [5] who found out that as many as 1/4 
of patients in the 6MWT did not improve or even 
deteriorated. It can be assumed that elderly pa-
tients and patients with comorbidities do not fully 
benefit immediately after the surgery. However, in 
the further period, still a large group of patients do 
not show any improvement in the 6MWT.
Moreover, there is a certain disproportion be-
tween the improvement in terms of the capacity of 
the cardiovascular system according to NYHA clas-
sification (approximate scale and difficult to assess in 
the elderly) and the fact that many patients reached 
no improvement in the 6MWT. This may result from 
qualifying for TAVI patients with severe stenosis of 
the aortic valve, and from the deterioration in exer-
cise tolerance as the main symptom. It is very dif-
ficult to determine in elderly patients, whether this 
symptom is closely associated with aortic stenosis. 
This may depend on other comorbidities, therefore 
no improvement is observed in some patients after 
properly conducted TAVI procedure.
The fact that a certain group of patients do not 
improve their condition may depend, as previously 
noted, on the comorbidities, such as the severity 
of coronary artery disease, incomplete revascu-
larization before TAVI, cardiomyopathies, mitral 
insufficiency, pulmonary hypertension, chronic 
obstructive pulmonary disease or common, at the 
older age, anemia and orthopedic problems.
Limitations of the study
The study was conducted in one center and 
included a small number of patients. Many patients 
could not arrive to participate in the study for 
logistic reasons.
Conclusions
1. After TAVI, a significant improvement in the 
6MWT distance was achieved in the 30-day 
follow-up and even greater improvements in 
the later period (6–12 months).
2. An improvement was reported in various pa-
rameters of the 6MWT in the 30-day follow-up 
— a higher pulse rate before and after the 
test, higher systolic blood pressure after the 
test, smaller value in the Borg scale and lower 
incidence of chest pain and breathlessness and 
dyspnea/fatigue after the test.
3. The 6–12-month follow-up showed significant 
improvements in individual parameters of the 
6MWT — higher pulse rate after the test, 
higher systolic and diastolic blood pressure 
before and after the test, and a lower incidence 
of chest pain. There was no improvement in 
the assessment of dyspnea according to the 
modified Borg scale and a significant reduction 
in dyspnea/fatigue after the 6MWT.
4. There was a significant improvement in effi-
ciency of the cardiovascular system evaluated 
according to NYHA classification after the TAVI 
in the 30-day and the 6–12-month follow-ups.
5. After TAVI, a significant improvement in 
echocardiographic parameters of aortic valve 
failure was recorded. During 30-day follow-
up and the 6–12-month follow-up increased: 
aortic valve surface area, index of the aortic 
valve surface area, and decreases the average 
gradient through the aortic valve.
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